Depression has been associated with both suppression and enhancement of various aspects of immune functioning. It was of interest to determine whether cytokine alterations associated with depression, including interleukin-1 (IL-1␤) and interleukin-2 (IL-2), were related to the neurovegetative symptom profile or to the chronicity of the illness. Circulating ACTH, cortisol, norepinephrine (NE) and epinephrine levels, and production of IL-1␤ and IL-2 from mitogen-stimulated lymphocytes were assessed in classical major depression, atypical depression (ie, with reversed neurovegetative features), and dysthymia (chronic depression without comorbid major depression) with either typical or atypical profiles, as well as nondepressed control subjects. Among atypical depressives, plasma ACTH levels were elevated while cortisol was reduced relative to controls. Irrespective of neurovegetative profile, IL-1␤ production was increased in dysthymic patients, and was highly correlated with age-of-onset and duration of illness. In contrast, IL-2 production was reduced in each of the groups, although less so among atypical major depressives. Moreover, IL-2 production in the depressive groups was directly related to plasma NE levels. While neither depressed mood per se nor neurovegetative features accounted for this effect, it seemed likely that chronicity of illness or age-of-onset were associated with cytokine alterations. Given that circulating cytokines influence neuroendocrine functioning, and may affect neurovegetative features, a role for interleukins may exist with respect to the pathophysiology of certain subtypes of depression.
Although major depression has been associated with suppression of some aspects of immune functioning, [1] [2] [3] [4] there have also been indications of immune activation, particularly in severely depressed (melancholic) patients. 3 The latter included an increased number of activated T cells (CD25 + and HLA-DR + ), [5] [6] [7] secretion of neopterin, prostaglandin E2 and thromboxane, [8] [9] [10] concentrations of soluble IL-2, IL-6 and transferrin receptors, [11] [12] [13] [14] as well as production of IL-1 and IL-6 in mitogen-stimulated cells. 3, 11 Inasmuch as IL-1 is a potent stimulator of CRH release, 15, 16 the possibility was also raised that this cytokine contributes to the altered HPA functioning characteristic of major depressive illness.
While not denying that severity of depression may be important in determining alterations in immune function, the possibility should also be considered that such effects may be related to either illness chronicity or to the neurovegetative symptoms of the disorder (eg, reduced sleep, appetite, and food consumption, which are among the characteristics of typical major depressive disorder). Indeed, immune alterations and variations of IL-1 activity can be induced in nondepressed subjects by brief sleep deprivation, 17, 18 as well as by stressful experiences. 19 Accordingly, it was of interest to assess the production of IL-1␤ and IL-2 in depressive patients differing with respect to neurovegetative characteristics. In contrast to major depressive illness, the atypical depressive profile comprises mood reactivity, coupled with reversed neurovegetative symptoms (hyperphagia, significant weight gain, hypersomnia), extreme fatigue and persistent rejection sensitivity which is not restricted to episodes of depression. [20] [21] [22] [23] Further, hypersecretion of corticotropin-releasing hormone (CRH) may be less prominent in atypical than in typical major depression, 24 and desipramine-elicited plasma cortisol secretion was greater in atypical patients, suggesting a less dysfunctional noradrenergic system. 20, 25 Additionally, atypical patients responded preferentially to MAOIs relative to tricyclic agents, [26] [27] [28] [29] particularly among females. 30 Although it was previously demonstrated that heightened IL-1␤ production was evident in melancholia (which excludes atypical features) and not minor depression, 3 it was of interest to establish whether cytokine alterations would be evident in chronic low-grade depression (dysthymia), and whether any such effect was dependent on the presence of typical vs atypical symptoms. It has been proposed that two subtypes of dysthymia exist, one of which may have a biological basis (subaffective) and the other being characterological in nature. 31, 32 The former is associated with early age-of-onset, and is amenable to pharmacotherapy. 33, 34 Unlike major depression, [34] [35] [36] dysthymia is not accompanied by elevations of plasma adrenocorticotrophic hormone (ACTH) and cortisol, nonsuppression of cortisol release following dexamethasone challenge, nor a blunted ACTH response to CRH challenge. 33, 34 In the present investigation we demonstrate that dysthymia, irrespective of the typical vs atypical features, is associated with elevated production of IL-1␤, and that such an effect may be related to either the age-of-onset or the duration of illness. Furthermore, the production of IL-2 in mitogen-stimulated cells was reduced in dysthymia and major depressive illness, and again this effect appeared to be independent of neurovegetative features. Table 1 shows the Hamilton Depression Rating Scores (HAM-D: 17-item) and the Montgomery Asberg Depression Rating Scale (MADRS) scores for each of the depressed groups, as well as the Beck Depression Inventory (BDI) scores for the control and depressive groups. The HAM-D and MADRS scores differed as a function of the Depressive subtype, F's (3,70) = 10.48, 11.63, P's Ͻ 0.01, stemming from the scores of the major depressive patients significantly exceeding those of the remaining depressive groups. The HAM-D scores of dysthymic patients were relatively high, owing in part to the frequent presence of anxiety and sleep disturbances, and the high HAM-D weightings of these symptoms. The difference between the typical major depressive and dysthymic patients is better reflected in the lower MADRS scores of the dysthymic patients.
While plasma norepinephrine (NE) and epinephrine levels did not vary as a function of the Affective Illness, levels of ACTH differed across groups, F(4,96) = 4.12, P Ͻ 0.01. Post hoc tests indicated that, relative to controls, ACTH levels were elevated in atypical major depressives, while in the typical major depressives a modest, nonsignificant increase of ACTH was apparent (see Table 2 ). In neither of the dysthymic groups was ACTH found to differ from controls. The levels of ACTH were also found to be higher in males, F(1, 91) = 4.75, P Ͻ 0.05, but this effect was only marked in the atypical major depressive patients. Further, plasma cortisol levels were lower in the two atypical than in the typical depressive conditions, F(1, 91) = 4.12, P Ͻ 0.05.
It appears that although affective illness may be associated with HPA dysfunction, elevations of ACTH were most pronounced in atypical major depression, while plasma cortisol levels were reduced. These data parallel reports indicating that disorders involving atypical depressive features (bulimia, seasonal affective disorder, and chronic fatigue syndrome) may be associated with elevated ACTH and reduced cortisol, possibly reflecting hypofunction of CRH neurons or adrenal insensitivity resulting in less feedback inhibition. 24, [37] [38] [39] [40] Of course, HPA disturbances associated with depressive disorders may occur at any number of different levels, and may involve more than a single dysfunctional mechanism. 36, 41 Thus, it is premature to assume that HPA disturbances in atypical depression involve the same mechanisms as those subserving other illnesses with atypical features. Furthermore, in the present investigation morning blood samples were collected over only a few minutes, and it remains to be determined whether a similar outcome would be evident with more protracted blood sampling over other phases of the diurnal cycle, particularly since cortisol and ACTH levels were not elevated in the typical major depressives.
The concentrations of IL-1␤ in the supernatants of mitogen-stimulated cells are shown in Figure 1 as a function of the affective condition. The concentrations of IL-1␤ increased with the dosage of PHA, F(2, 192) = 59.36, P Ͻ 0.01, and varied as a function of the Affective illness, F(4, 96) = 5.02, P Ͻ 0.01. Newman-Keuls multiple comparisons confirmed that relative to control subjects the concentrations of IL-1␤ were not affected in either the major depressive or the atypical depressive patients. In contrast, IL-1␤ was significantly elevated among the dysthymic patients, irrespective of whether they exhibited typical or atypical features. Parenthetically, although catheter insertion itself may promote local inflammation and hence increased cytokine production, the short duration of catheterization (ie, 30 min) was not sufficient to elicit cytokine variations. Moreover, since the elevated IL-1␤ production was only evident in dysthymic patients, it is unlikely that local inflammation contributed to the observed outcome.
Production of IL-2 varied as a function of affective condition × mitogen dosage interaction, F(4, 180) = 2.33, P Ͻ 0.05. At the lowest mitogen dose none of the groups differed from one another; however, at the remaining two mitogen doses, IL-2 production was significantly reduced in the two dysthymic groups and in the atypical major depressive patients relative to nondepressed controls (see Figure 1) . The reductions of mitogen-stimulated IL-2 were less profound in the typical major depressive patients, although a significant IL-2 reduction was observed at the highest PHA concentration.
The finding that IL-1␤ production was elevated in dysthymic patients, and not in either the typical or atypical major depressives, was unexpected. It is of course possible that alternate types of assays for cytokine production may have yielded different results. For instance, the use of PHA combined with LPS to stimulate cells in whole blood may have provided a better indication of cytokine production from macrophages and T cells than that observed in assays involving mitogen-stimulated mononuclear cells. 42 Inasmuch as dysthymia is a chronic illness, often associated with early age-of-onset, either of these variables may have contributed to the altered IL-1␤ production. Accordingly, Pearson Product Moment correlations were conducted between IL-1␤ levels (at each mitogen dosage) and the age-of-onset and chronicity of dysthymia. In fact, both these variables were found to be highly correlated with the IL-1␤ concentrations. In particular, the correlations between age-of-onset and IL-1␤ (at the 1.0, 3.0 and 5.0 g doses of PHA) were found to be −0.58, −0.44 and −0.50, P Ͻ 0.01, respectively, while the correlations between duration of illness and IL-1 were 0.60, 0.46 and 0.43, P's Ͻ 0.01, respectively. In contrast, neither age-of-onset nor duration of illness were significantly correlated with IL-2 levels. Furthermore, levels of IL-1 and IL-2 were unrelated to age-of-onset or duration of illness in major depressive patients. Likewise, in none of the groups was age itself found to be correlated with the cytokine levels.
Since cortisol has been reported to inhibit cytokine production, 43 while NE stimulates lymphocyte activity, 44 correlations were conducted between production of IL-1␤ and IL-2 and plasma neuroendocrine concentrations. These analyses indicated that the correlations between IL-1 production (after 1.0, 3.0 or 5.0 g of PHA) and levels of cortisol, ACTH and NE were nonsignificant among both major depressive and dysthymic patients. Likewise, plasma cortisol levels were not correlated with IL-2 production. However, the production of IL-2 was highly correlated with NE concentrations in both these patient groups. Specifically, among dysthymic patients the correlations between NE levels and IL-2 production (following 1.0, 3.0 and 5.0 g of PHA) were 0.45, 0.57 and 0.54, respectively, while in the major depressive patients these correlations were 0.52, 0.43 and 0.50 (P's Ͻ 0.05). Among control subjects the correlation between IL-2 production and NE was low (0.03, 0.08 and 0.14).
Summarizing, although it had been expected that IL-1␤ and IL-2 production would differ with typical and atypical depressive profiles, such an outcome was not observed. While neurovegetative factors may affect some aspects of immune functioning, 17, 18, 45 these neurovegetative factors did not account for the IL-1␤ variations observed in depressive illness. However, major depressive and dysthymic patients (both typical and atypical) could be distinguished from one another on the basis of their cytokine profiles. Specifically, IL-1␤ production was elevated primarily in dysthymia, and the extent of the increase was correlated with the ageof-onset and the chronicity of the illness, rather than simply reflecting the presence of a mood disorder.
The increased IL-1␤ production is one of few physiological characteristics that distinguish dysthymic patients from both major depressive and control populations. It will be recalled that the HPA disturbances which characterize major depression (as evidenced following dexamethasone and/or CRH challenge) are not observed in dysthymic patients. 33, 34, 46 Also, growth hormone secretion in response to physiological challenges, as well as thyroid stimulating hormone blunting in response to TRH, are less likely to occur in dysthymia as in major depression. 33, 34 While neuroendocrine disturbances may occur primarily among early illness onset dysthymics, 47 there are few neuroendocrine studies that distinguished between dysthymic and nondepressed subjects. In part, this may stem from the subtle pathophysiological disturbances in dysthymia, and the use of neuroendocrine analyses that tap circulating hormonal levels rather than the temporal patterns of hormone release. 48 Yet, as IL-1␤ is a potent stimulator of CRH release, the production of this cytokine may be an essential component of the neuroendocrine cascade characterizing dysthymia.
The view was offered, it will be recalled, that depression may be associated with the enhancement of some components of the immune response (much like an acute phase reaction), which may ultimately promote suppression of other aspects of immune functioning. 3 Among other things, mitogen-induced IL-1␤ and IL-6 production was increased in blood mononuclear cells of severely depressed patients. 3 While not excluding the possibility that illness severity may be a pertinent feature in promoting the enhanced IL-1␤ production (after all, melancholic patients were not assessed in the present study), it seems likely that illness chronicity or age-of-onset may be important in this respect, as well. Dysthymia is a chronic illness and is associated with increased stress perception and inadequate coping styles, 34 and as such some of the neuroendocrine characteristics of a chronic stressor may be engendered in these patients. For instance, chronic stress may be associated with phenotypic variations of CRH neurons within the paraventricular nucleus, such that they coexpress arginine vasopressin (AVP) and CRH. 49 The fact that dysthymic patients do not exhibit increased ACTH and cortisol, and even display reduced cortisol levels, 34 necessitates evaluation of the effects of various challenges in dysthymic patients (eg, ACTH, CRH, AVP, as well as serotonergic acting agents) in order to identify the nature of the HPA dysfunctions. 36, 50 At this juncture it is not clear whether the cytokine alterations in dysthymia are related to HPA functioning. However given the well documented interactions between cytokines and endocrine systems, such a possibility needs to be considered, 51 despite the fact that plasma cortisol levels in the present investigation were unrelated to IL-1␤ production in either dysthymic or major depressive patients.
In contrast to the increased IL-1␤ in supernatants of mitogen-stimulated lymphocytes, we have observed that circulating serum IL-1␤ measured was not increased in either typical major depressive or in dysthymic patients. However, among atypical major depressive patients, circulating IL-1␤ levels were greatly increased, and normalized with antidepressant treatment. 52 It could be assumed that the elevated levels of IL-1␤ seen in atypical depression may be secondary to the neurovegetative features of this depressive subtype. However, animal studies have shown that IL-1␤ provokes illness behaviors (including increased sleep and fatigue), 53 and thus it is just as likely that elevated circulating IL-1␤ contributes to the neurovegetative features of atypical depression. The finding that illnesses involving atypical depressive features (eg, chronic fatigue syndrome) may be associated with HPA disturbances (eg, reduced plasma cortisol, increased ACTH, and reduced ACTH release following oCRH challenge), 37, 38 coupled with the fact that IL-1␤ is a potent stimulator of CRH release, 14 raises the possibility that elevated circulating IL-1␤ levels contribute to the pathophysiology of atypical depression.
In contrast to IL-1␤, mitogen-stimulated IL-2 levels were appreciably reduced irrespective of whether patients presented with typical or atypical features, or whether patients fit the dysthymic or major depressive profile. The reduced IL-2 production was highly correlated with plasma NE levels in both depressive groups, possibly reflecting characteristics of NE receptors on lymphocytes of depressive subjects. At first blush, the reduced IL-2 production may be taken to suggest that this aspect of immune functioning, insofar as it may reflect T cell activation, is impaired in depression. However, the net action of IL-2 is dependent upon the levels of soluble IL-2 receptors, and measurement of IL-2 in vitro is hampered by the binding of the cytokine to its receptor, a problem which can be overcome by adding anti-Tac (an IL-2 receptor blocking antibody) to the culture. 54 Since anti-Tac was not used in the present investigation, it cannot be said with any certainty whether depressive illness was associated with reduced IL-2 or altered binding with IL-2 receptors. However, we recently observed cell proliferation stimulated by the T-cell cell mitogens, PHA and Con-A, to be profoundly reduced in dysthymic patients, but only modest reductions were seen in typical and atypical major depressive patients. 52 Thus, depressive illness may indeed be associated with impairment of some aspects of immune functioning, and once again illness chronicity or age-of-onset may be determining factors in this respect.
Methods

Subjects
The age of the subjects, number of males and females (in parentheses), HAM-D, MADRS and BDI scores are shown in Table 1 . The patients were consecutive referrals to the Mood Disorders Clinic (outpatients) of the Royal Ottawa Hospital, who satisfied the required inclusion/exclusion criteria. Patients in the depressed groups fulfilled the DSM-IIIR/DSM-IV criteria for the respective disorders, and were, at the time of diagnosis, free of any other Axis I disorders. In both the major depressive and in the atypical groups illness severity was classified as moderate using the Clinical Global Impressions scale for severity (CGI). Patients with dysthymia were free of concurrent major depression. Previous history of depression was excluded on the basis of patient self-report. While patients were free of Axis II disorders, the depressive groups tended to have personality traits particularly of a dependent, obsessive or avoidant nature. There was, however, no evidence of personality disorder, and no difference in the frequency of personality traits among these groups.
Patients were assessed using the 29-item HAM-D; the first 17 items were used as a measure of illness severity, while items 23-28 were used to detect atypical features. Patients diagnosed with atypical depression scored Ͼ6 on items 23-28, inclusive, on the 29-item HAM-D and fulfilled the Columbia criteria for atypical depression with a score of Ն4 on the Atypical Depression Diagnostic Scales (ADDS). The dysthymic patients had a diagnosis of primary dysthymia, and met Akiskal's criteria for subaffective subtype. 55 These patients were also classified as exhibiting either typical or atypical features based on items 23-28 of the 29-item HAM-D scale, and none of these patients met the criteria for concurrent major depression.
The nondepressed control subjects, who comprised volunteer blue-and white-collar hospital employees, government employees and part-time University students were obtained through advertisements. The volunteers were screened using a semistructured clinical interview (M.I.N.I) 56 to exclude past or present DSM-III-R/DSM-IV axis I disorders, had BDI scores of less than 4, and scored 0 on the first question of this scale ('I do not feel sad'), 57 and had never been treated with psychotropic medications. Exclusion criteria for all subjects in the investigation also included self-reported viral illness during the preceding 2 weeks, as well as severe allergies, hypertension, significant recurrent dermatitis, malignant, hematologic, endocrine, pulmonary, cardiovascular, renal, hepatic, gastrointestinal or neurologic disease, or any medical disorder that required drug treatment which may have affected immune activity (eg, glucocorticoids). All subjects reported fewer than 5.0 alcoholic drinks/week, 3.0 cups of coffee/tea or less per day, and had not used any elicit drugs during the preceding 6 months. After complete description of the study to the subjects, written informed consent was obtained.
Procedures
Data gathered during the screen visit included demographic information, characteristics of the current episode among the depressed patients, and past history and family history of psychiatric illness. Patients underwent a full physical examination and clinical evaluation which included full blood count, urinalysis, and EKG. Symptoms of depression were measured using standardized instruments, including the HAM-D, MADRS, and the BDI. After the screen visit all patients underwent a 1-week wash-out period. The protocol called for those subjects undergoing treatment with psychotropic medication (less than 5% of the subjects) to undergo a further wash-out equivalent to five times the half-life of the medication they had received (eg 5-week wash-out for fluoxetine, 4-week wash-out for MAO-Is, 1 week for most other antidepressant agents).
On the test day, between 0700 and 0930 h, subjects had a catheter inserted into the antecubital fossa of their arm, and sat comfortably in a sofa chair while watching a neutral videotape. Using a Dakmed ambulatory pump, blood was withdrawn automatically over 10 min, commencing 20 min after catheter insertion. Aliquots of blood pooled over this period were used as single samples for assay of the various hormones and for mitogen-stimulated cytokines. This time period was previously found to permit stabilization of plasma ACTH and cortisol levels associated with catheterization. Tubes used for cortisol, ACTH and plasma amine determinations contained EDTA, while samples used for IL-1␤ and IL-2 determinations contained sodium heparin. Plasma samples used for endocrine analyses were quickly frozen and stored at −70°C.
Assay procedures
Cortisol and ACTH were determined, in duplicate, using standard RIA kits obtained from ICN (Montreal, Quebec, Canada). The interassay coefficients of variability for cortisol and ACTH were less than 10%, while the intra-assay coefficients were less than 7%. Plasma norepinephrine and epinephrine were determined by HPLC 58 in a single run as previously described, 59 and also showed less than 10% intra-assay variability.
To determine mitogen-stimulated IL-1␤ and IL-2 production, mononuclear cells were isolated by layering whole blood onto Histopaque-1077 (Sigma) in a 1:1 dilution in a conical tube and centrifuged (400 × g) for 30 min at room temperature. The mononuclear fraction was washed in PBS containing streptomycin (× 3), and centrifuged at 400 × g for 10 min at 4°C. The supernatant was discarded, and the cells resuspended in 5.0 ml of complete RPMI (containing 10% fetal calf serum). Mononuclear cells were counted and adjusted to 1 × 10 6 ml −1 in complete RPMI. PHA was added (0, 1, 3 or 5 g in a volume of 100 l) to 1 × 10 6 cells in RPMI containing 10% fetal calf serum, penicillin-streptomycin (10 000 IU L −1 ), streptomycin (10 000 g L −1 ) and sodium pyruvate (0.5 ml L −1 ). The plates were incubated for 72 h in 5% CO 2 at 37°C, and then centrifuged, the supernatant removed and stored at −80°C. Concentrations of IL-1␤ and IL-2 were determined by ELISA, in duplicate, in 96-well flat-bottomed titer plates, using kits obtained from R & D systems (Minneapolis, MN, USA).
Statistical analysies
Analyses of variance were performed to determine cytokine and endocrine differences as a function of the affective disorder. Comparisons between individual group means were conducted by Newman-Keuls multiple comparisons (␣ = 0.05), or by orthogonal contrasts when two groups were simultaneously compared to two other groups (eg, comparisons of the typical vs the atypical groups, or major depressive vs dysthymic groups). Unless otherwise indicated the scores were not found to vary as a function of either Sex or the interaction between Sex and Diagnostic category. During the course of the experiment problems were encountered during an endocrine or immune assay. Accordingly, the degrees of freedom for the analyses varied across the different dependent measures. Relations between endocrine and cytokine measures, as well as between illness characteristics and cytokine concentrations were determined by Pearson Product Moment correlations.
